Sharing the cost of expensive new cancer medicine with drugs companies is becoming increasingly common but the complexity of the reimbursement procedure means around half the total costs are not being recovered.
The Department of Health said it is trying to make the payment-sharing schemes more simple.
Consultant pharmacist Steve Williamson, who works at Northumbria Healthcare Foundation Trust, wrote in the Clinical Pharmacist journal that he welcomed the practice of making cancer drugs more widely available but said complicated paperwork is making the reimbursement procedure unworkable.
via hsj.co.uk
1 comment:
Who organized the reimbursement system? I could see drug companies purposefully making it difficult just so they wouldn't have to shell out as much cash.
Post a Comment